9 Best Psychedelic Stocks to Buy in 2026
The AdvisorShares Psychedelics ETF, a fund that primarily invests in the psychedelic drugs sector, is up 31% over the past year. That almost doubles the S&P 500’s 16% gain over the same timeframe.
Cybin Inc. (HELP)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Point72 Asset Management Steve Cohen | 4,432,559 | $36,258,333 | +258% | 0.04% |
| 2. | OrbiMed Advisors Samuel Isaly | 3,840,500 | $31,415,290 | 0.64% | |
| 3. | Deep Track Capital David Kroin | 1,854,255 | $15,167,806 | +86% | 0.27% |
| 4. | Millennium Management Israel Englander | 1,028,549 | $8,413,531 | +1389% | 0% |
| 5. | Sphera Global Healthcare Fund Doron Breen And Mori Arkin | 825,576 | $6,753,212 | +123% | 1.31% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 238,302 | $1,143,850 | 0% | |
| 2. | 195,604 | $938,899 | 0.17% | |
| 3. | 36,421 | $174,821 | 0.11% | |
| 4. | 30,344 | $145,499 | 0.01% | |
| 5. | 10,649 | $87,109 | 0.01% |
News See All
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)'s Science-Driven Psilocybin Therapies as Key Growth Drivers
TheFly reported on February 2 that Jefferies initiated coverage of HELP with a Buy rating and a $22 price target and also highlighted significant upside potential.
7 Most Promising Psychedelic Stocks According to Hedge Funds
The psychedelic industry is poised to have a significant "second wave," transforming from a speculative, counterculture-driven movement into a recognized cornerstone of the US healthcare system.
Hedge Fund Resource Center